

IMMUNOGEN INC  
Form 4  
November 29, 2007

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
SAYARE MITCHEL

(Last) (First) (Middle)

C/O IMMUNOGEN, INC., 128  
SIDNEY STREET

(Street)

CAMBRIDGE, MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
IMMUNOGEN INC [IMGN]

3. Date of Earliest Transaction  
(Month/Day/Year)  
11/27/2007

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)

Chief Executive Officer

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount or Price		
Common Stock	11/27/2007		M		11,500 A \$ 0.844	537,778	D
Common Stock	11/27/2007		S		1,700 D \$ 4.84	536,078	D
Common Stock	11/27/2007		S		1,300 D \$ 4.82	534,778	D
Common Stock	11/27/2007		S		1,100 D \$ 4.81	533,678	D
Common Stock	11/27/2007		S		1,261 D \$ 4.8	532,417	D

Edgar Filing: IMMUNOGEN INC - Form 4

Common Stock	11/27/2007	S	2,039	D	\$ 4.83	530,378	D
Common Stock	11/27/2007	S	800	D	\$ 4.79	529,578	D
Common Stock	11/27/2007	S	300	D	\$ 4.78	529,278	D
Common Stock	11/27/2007	S	1,800	D	\$ 4.86	527,478	D
Common Stock	11/27/2007	S	300	D	\$ 4.85	527,178	D
Common Stock	11/27/2007	S	200	D	\$ 4.88	526,978	D
Common Stock	11/27/2007	S	400	D	\$ 4.87	526,578	D
Common Stock	11/27/2007	S	300	D	\$ 4.89	526,278	D
Common Stock	11/28/2007	M	29,300	A	\$ 0.844	555,578	D
Common Stock	11/28/2007	S	2,000	D	\$ 4.845	553,578	D
Common Stock	11/28/2007	S	800	D	\$ 4.92	552,778	D
Common Stock	11/28/2007	S	244	D	\$ 4.88	552,534	D
Common Stock	11/28/2007	S	100	D	\$ 4.79	552,434	D
Common Stock	11/28/2007	S	128	D	\$ 4.77	552,306	D
Common Stock	11/28/2007	S	372	D	\$ 4.78	551,934	D
Common Stock	11/28/2007	S	4,051	D	\$ 4.8	547,883	D
Common Stock	11/28/2007	S	200	D	\$ 4.87	547,683	D
Common Stock	11/28/2007	S	1,100	D	\$ 4.81	546,583	D
Common Stock	11/28/2007	S	609	D	\$ 4.86	545,974	D
Common Stock	11/28/2007	S	3,907	D	\$ 4.84	542,067	D
	11/28/2007	S	121	D	\$ 4.9	541,946	D

Edgar Filing: IMMUNOGEN INC - Form 4

Common  
Stock

Common Stock	11/28/2007	S	3,786	D	\$ 4.85	538,160	D
Common Stock	11/28/2007	S	9,682	D	\$ 4.83	528,478	D
Common Stock	11/28/2007	S	2,200	D	\$ 4.82	526,278	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Security (Instr. 3 and 4)
Non-qualified stock option (right to buy)	\$ 0.844	11/27/2007		M	11,500	12/31/1998 <sup>(1)</sup> 12/31/2007	Common Stock
Non-qualified stock option (right to buy)	\$ 0.844	11/28/2007		M	29,300	12/31/1998 <sup>(1)</sup> 12/31/2007	Common Stock

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
SAYARE MITCHEL C/O IMMUNOGEN, INC. 128 SIDNEY STREET CAMBRIDGE, MA 02139	X		Chief Executive Officer	

## Signatures

/s/ Daniel M. Junius, attorney  
in fact

11/29/2007

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Exercisable as to 76,389 shares commencing on December 31, 1998, 76,389 shares commencing on December 31, 1999, and 76,388 shares commencing on December 31, 2000.
- (2) Field N/A to this transaction but was completed to allow for electronic filing only.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.  
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.